博客栏目停服公告
因网站改版更新,从9月1日零时起美国中文网将不再保留博客栏目,请各位博主自行做好备份,由此带来的不便我们深感歉意,同时欢迎 广大网友入驻新平台!
美国中文网
2024.8.8
|
通过检索国际体育上诉法庭听证会文件,关于瓦利耶娃样本药物浓度及相关专家证词事实如下:
第一,样本浓度为2.1ng/ml。
第二,检测的技术下限为10ng/ml。
第三,专家证言一个运动员口服一片35毫克曲美他嗪后一天,尿样本浓度应该为960-9000ng/ml。2ng/ml 如果是口服摄入,起码是在5到7天前。
第四,瓦利耶娃团队认为由于样本浓度极度低下,存在污染和技术错误的可能性。要求对B样本进行检测。法庭采纳其要求。
相关文字段落拷贝如下:
The concentration of Trimetazidine detected was estimated at 2.1 ng/ mL
single use of a dose of 35mg TMZ leads to a concentration of the substance in a sample a day later between 966 ng/ml 9000 ng/ ml. A concentration of 2 ng/ ml would require a single use of 35 mg a minimum 5 – 7 days before the competition.
Moreover, the DADC also took into consideration that the Athlete's legal representative disputed the positive results of the Sample alleging that the concentration of 2.1 ng/ml, is well below the technical limit of detection of Trimetazidine , which is 10 ng/ml, and may be a technical mistake of the sample analysis in the laboratory and she confirmed at the hearing the intention to request the analysis of the “ B ” sample.